Skip to content

Tramadol Hydrochloride: US FDA label indications

US FDA labelNot medical advice

Label details

Brand name
Tramadol Hydrochloride
Generic name
Tramadol Hydrochloride
Manufacturer
Proficient Rx LP
Route
Oral
Product type
Human Prescription Drug
Substance
Tramadol Hydrochloride
Application number
ANDA201384

Indications and usage (label excerpt)

INDICATIONS AND USAGE Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Warnings (label excerpt)

WARNINGS Seizure Risk Seizures have been reported in patients receiving tramadol within the recommended dosage range. Spontaneous postmarketing reports indicate that seizure risk is increased with doses of tramadol above the recommended range. Concomitant use of tramadol increases the seizure risk in patients taking: • Selective serotonin re-uptake inhibitors (SSRI antidepressants or anorectics), • Tricyclic antidepressants (TCAs), and other tricyclic compounds (e.g., cyclobenzaprine, promethazine, etc.), or • Other opioids. Administration of tramadol may enhance the seizure risk in patients taking: • MAO inhibitors (see also WARNINGS - Use with MAO Inhibitors ), • Neuroleptics, or • Other drugs that reduce the seizure threshold. Risk of convulsions may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (such as head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections). In tramadol overdose, …

Excerpts are shortened. Read the full label, and ask a pharmacist or prescriber about any medicine. Full label on DailyMed(opens in a new tab) For products sold in Canada, see the Health Canada Drug Product Database(opens in a new tab).

Trials whose interventions mention this drug

Canadian trials first. A match on the drug name does not mean the trial studied this specific product.

5 trials, recruiting first
PhaseCountries
Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain
NCT05125978
WithdrawnPhase 2EMS2026-09
Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain
NCT04589494
Unknown statusPhase 2, Phase 3EgyptAssiut University2020-04-16
An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain
NCT00736853
CompletedPhase 3JapanJanssen Pharmaceutical K.K.2008-06
A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain
NCT00736957
CompletedPhase 3JapanJanssen Pharmaceutical K.K.2008-05
Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.
NCT00290901
CompletedPhase 4Puerto Rico, United StatesPfizer's Upjohn has merged with Mylan to form Viatris Inc.2006-03

Source: openFDA drug label (US FDA), snapshot October 2026. Not a Health Canada Product Monograph.